IsoPlexis Corp

IsoPlexis — Investor Presentation (September 2022)

24 slides from IsoPlexis's investor presentation, Sep 12, 2022

  1. Slide 1: Empowering Labs, Changing Human Health

    September 2022 EMPOWERING LABS, CHANGING HUMAN HEALTH

  2. Slide 2: Disclaimer and Forward-Looking Statements

    Disclaimer and Forward-Looking Statements Forward-looking statements and other information This presentation contains “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are

  3. Slide 3: We Empower Labs to Leverage the Cells & Proteome Changing the Course of Human Health

    WE EMPOWER LABS TO LEVERAGE THE CELLS & PROTEOME CHANGING THE COURSE OF HUMAN HEALTH

  4. Slide 4: Our Differentiated Lab Tools are Empowering the Field

    Our Differentiated Lab Tools are Empowering the Field 4 100% OF TOP 15 PHARMA 2 78% OF COMPREHENSIVE CANCER CENTERS 3 112 PUBLICATIONS 254 INSTRUMENTS IN THE FIELD $18.7M TTM REVENUE 1 • Differentiated, High Need Product Positioning: Cell behavior & proteome workflow • Easy to Access package: Small,

  5. Slide 5: Key Growth Initiatives Driving IsoPlexis

    Key Growth Initiatives Driving IsoPlexis 5 Cellular Behavior Proteomic Multiomics Effortless Proteomics + • Commercial Growth: Drive continued velocity of 254 instrument base & flexibility of applications, demonstrating ability to ‘land and expand’ with installed base, increasing ‘razorblade’ consum

  6. Slide 6: Evolving One Benchtop Platform into Mass Market Opportunities

    Evolving One Benchtop Platform into 3 Mass Market Opportunities Coverage of Majority Cell Types Flexible Cytometry: All proteins 2022 20232021 Phospho- proteomics across cells Each Advancement increases addressable market by 2-5x 18 inches Early Access + Data Effortless Proteomics: Cytokines Early A

  7. Slide 7: Unique ISO Products are Increasingly Positioned for Mass Market Users

    Unique ISO Products are Increasingly Positioned for Mass Market Users 7 CodePlex Bulk Proteomics Unique Effortless Workflow, Throughput, Cost vs. Multiplexed Proteomics • Launching workflow automates 90% labor, 80% less sample, 25% less cost • Fulfilling demand of proteomics users to eliminate workf

  8. Slide 8: IsoCode: Highly Differentiated Cell Behavior Analysis vs. Flow Cytometry

    IsoCode: Highly Differentiated Cell Behavior Analysis vs. Flow Cytometry 8 Cytokines / Output Proteins per Cell Few New Dimension of Cell Behavior Surface Marker per Cell Many Adding ISO Flexibility for flow users Ease of Cytokine Workflow ✓  Ease of Use of Instrument & Software Miniaturized System

  9. Slide 9: Ease of End to End Cell Analysis Workflow is Key

    Ease of End to End Cell Analysis Workflow is Key 9 RANGE OF CELL TYPES & PROTEIN PANELS LAB’S NEED REAGENTS UNIQUE TO OUR SYSTEM: FLOW CELLS EFFORTLESSLY AUTOMATED, SMALL FOOTPRINT ANALYTICS THAT DON’T REQUIRE TECHNICIANS IsoCode™ Chip IsoLight™ & IsoSpark™ IsoSpeak™ 1 See IsoPlexis website for anno

  10. Slide 10: Cell flexibility on system has expanded significantly, expanding market

    Cell flexibility on system has expanded significantly, expanding market Extracellular Matrix / Cardio/vascular 10 Cells of the Central Nervous System Broader Immune lineages Tumor Cells of all types Vascular /Transplant Biology COVID & Infectious Disease Tumor Cell Profiling Cell Matrix / Cells BROA

  11. Slide 11: Increasing Cell Analysis Flexibility for Comprehensive Cellular Biology

    30+ Cytokines, Chemokines, Growth Factors (‘20) 15+ Phosphoproteins, Translation, Transcription Factors (‘21) 15+ Integrated Phosphoproteins & Cytokines (‘22) Increasing Cell Analysis Flexibility for Comprehensive Cellular Biology 11 3 Lasers: Today Adding Cytometry Flexibility Adding Key Multiplexe

  12. Slide 12: CodePlex: Effortless Proteomics Made for This Moment

    CodePlex™: Effortless Proteomics Made for This Moment 121 Multiplexed bead based ELISA workflow; 2 Consulting research; 3 * Current and future targeted panel sizes, starting with Panels around 20 plex range 5 - 503 Proteins Per Sample* 17,0002 System TAM 15+ Steps1 → 1 Step Effortlessly Automated Wo

  13. Slide 13: CodePlex Addresses Customer Pain Points vs. Status Quo

    CodePlex Addresses Customer Pain Points vs. Status Quo 13 CHANGING WORKFORCE demanding more time away from the bench, ie. effortless workflows RESULTS DRIVEN all labs need confidence to move forward, with gold standard proteomics PRECIOUS SAMPLES samples, whether fresh or banked, are valuable & hard

  14. Slide 14: Bulk Multiplexed Proteomics: Codeplex & the Workflow Opportunity

    Bulk Multiplexed Proteomics: Codeplex & the Workflow Opportunity 14 Traditional Bead-Based Methods Laborious and difficult workflow • Flexible analytes • Customer familiarity • Tedious workflow • Performance affected by workflow • High sample volume • High sensitivity • Very high multiplex capabilit

  15. Slide 15: Traditional vs. Codeplex Bulk Proteomic Workflow

    Traditional vs. Codeplex Bulk Proteomic Workflow 15 Codeplex

  16. Slide 16: Over 75% of Proteomics Customers Choose Mid-Plex, Codeplex' Specialty

    Over 75% of Proteomics Customers Choose Mid-Plex, Codeplex’ Specialty 16 Proteomics Survey: Approximately how many cytokines or other protein markers do you feel you need to measure to create an accurate profile of cellular function? 1-5 14% 6-10 31% 11-15 17% 16-20 19% 21-25 9% 26-30 5% 31-40 1% 41

  17. Slide 17: It's Bulk Multiplexed Proteome Analysis Without the Bulky Process

    It’s Bulk Multiplexed Proteome Analysis Without the Bulky Process 17 Prepare Reagents 1 pipette action per sample triplicate Load Instrument Fully Automated Effortless Workflow CodePlex Platform Traditional Method Prepare Reagents 12-18 hr Incubate 20 min Wash x3 20 min Export data ? Add samples to

  18. Slide 18: What does CodePlex Deliver?

    What does CodePlex Deliver? • 20 sample chambers per chip (80 per run) at launch • 30 sample chambers per chip (120 per run) in later ‘23 • 5 – 50 plex Assays • <10uL sample per chamber • < 30 min hands on time for assay set up • </= 15% CVs (within a single chip and across chips) • Built-in triplic

  19. Slide 19: Duomic: IsoPlexis Will Drive Leadership in Proteomic Driven Multiomics

    Phosphoproteins Cytokines, Chemokines, Growth Factors Duomic: IsoPlexis Will Drive Leadership in Proteomic Driven Multiomics 19 Proteomic Driven Multi-omics in Single Cell Biology will drive Pre-Clinical and Translational Medicine: Late 2023 as Service IsoPlexis is the only company to provide functi

  20. Slide 20: Full Workflow for Duomic, Powered by Proteome + Transcriptome

    Full Workflow for Duomic, Powered by Proteome + Transcriptome 20 cDNA IsoZipCode™: mRNA Capture Proteomic Barcode: Protein Capture Bead w/ Unique Cellular Identifier + IsoZipCode Illustrative Schematic of Duomic workflow Single-Cell Proteome from Chamber 250 Chamber #250 Transcriptome Proteome

  21. Slide 21: Duomic Will Open Up New, Clinically Relevant Multiomic Markets

    Duomic Will Open Up New, Clinically Relevant Multiomic Markets 21 Nature Method of the Year: Single-Cell Multimodal omicsNature Method of the Year: Single-Cell Gene expression Duomic’s novel proteomic analytes enable large, new multiomic opportunities in medicine 2013 2019

  22. Slide 22: Foundational Patents Issued and Filed Underpins Continued Expansion

    167 Foundational Patents Issued and Filed Underpins Continued Expansion 22 IsoSpark IsoSpeak CodePlex Secretome CodePlex Metabolome CodePlex Intracellular Proteome Single-Cell Secretome Single-Cell Intracellular Proteome Single-Cell Metabolome Single-Cell Sequencing & Protein IsoLight 167 PROTEOMICS

  23. Slide 23: Empowering Labs to Leverage Cellular & Proteomic Biology to Advance Health

    23 To cell behavior and proteomics being accessible to every lab – driving proteomic driven health Cellular Behavior Proteomic Multiomics Effortless Proteomics + Empowering Labs to Leverage Cellular & Proteomic Biology to Advance Health Going from a world where access to the right cells and proteome

  24. Slide 24: © 2022 IsoPlexis | All Rights Reserved

    © 2022 ISOPLEXIS | ALL RIGHTS RESERVED For Research Use Only. Not for Use in Diagnostic Procedures.

IsoPlexis — Investor Presentation (September 2022) on 6ix